ES2949276T3 - Evaluación de la insuficiencia circulatoria - Google Patents
Evaluación de la insuficiencia circulatoria Download PDFInfo
- Publication number
- ES2949276T3 ES2949276T3 ES14701757T ES14701757T ES2949276T3 ES 2949276 T3 ES2949276 T3 ES 2949276T3 ES 14701757 T ES14701757 T ES 14701757T ES 14701757 T ES14701757 T ES 14701757T ES 2949276 T3 ES2949276 T3 ES 2949276T3
- Authority
- ES
- Spain
- Prior art keywords
- heterogeneity
- skin
- microcirculation
- subject
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010009192 Circulatory collapse Diseases 0.000 title claims abstract description 61
- 206010040560 shock Diseases 0.000 title claims abstract description 61
- 238000011156 evaluation Methods 0.000 title claims description 32
- 238000000034 method Methods 0.000 claims abstract description 94
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 72
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 72
- 239000001301 oxygen Substances 0.000 claims abstract description 72
- 230000004089 microcirculation Effects 0.000 claims abstract description 67
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 32
- 238000001055 reflectance spectroscopy Methods 0.000 claims abstract description 17
- 238000000386 microscopy Methods 0.000 claims abstract description 15
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 claims description 80
- 238000004458 analytical method Methods 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 31
- 238000004393 prognosis Methods 0.000 claims description 24
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 206010065929 Cardiovascular insufficiency Diseases 0.000 claims description 18
- 238000001228 spectrum Methods 0.000 claims description 18
- 230000007170 pathology Effects 0.000 claims description 17
- 238000010865 video microscopy Methods 0.000 claims description 15
- 206010040047 Sepsis Diseases 0.000 claims description 13
- 201000004193 respiratory failure Diseases 0.000 claims description 13
- 238000012545 processing Methods 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 201000011384 erythromelalgia Diseases 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 6
- 201000002818 limb ischemia Diseases 0.000 claims description 5
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims 3
- 206010009126 Chronic respiratory failure Diseases 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 claims 1
- 206010001053 acute respiratory failure Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 abstract description 15
- 238000005259 measurement Methods 0.000 description 87
- 210000003491 skin Anatomy 0.000 description 78
- 230000010412 perfusion Effects 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 25
- 210000004088 microvessel Anatomy 0.000 description 24
- 210000000038 chest Anatomy 0.000 description 21
- 125000001475 halogen functional group Chemical group 0.000 description 18
- 208000032843 Hemorrhage Diseases 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 239000000835 fiber Substances 0.000 description 16
- 210000003414 extremity Anatomy 0.000 description 14
- 210000002683 foot Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 235000016709 nutrition Nutrition 0.000 description 12
- 230000009885 systemic effect Effects 0.000 description 12
- 206010021143 Hypoxia Diseases 0.000 description 11
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000007954 hypoxia Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000004087 circulation Effects 0.000 description 9
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 206010007625 cardiogenic shock Diseases 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000003128 head Anatomy 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 238000010837 poor prognosis Methods 0.000 description 8
- 230000003595 spectral effect Effects 0.000 description 8
- 230000034994 death Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000002266 amputation Methods 0.000 description 6
- 208000034158 bleeding Diseases 0.000 description 6
- 231100000319 bleeding Toxicity 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000000004 hemodynamic effect Effects 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 230000001331 thermoregulatory effect Effects 0.000 description 6
- 238000012384 transportation and delivery Methods 0.000 description 6
- -1 tungsten halogen Chemical class 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000004247 hand Anatomy 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- 230000003319 supportive effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 108010054147 Hemoglobins Chemical class 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical class O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 208000034486 Multi-organ failure Diseases 0.000 description 4
- 208000010718 Multiple Organ Failure Diseases 0.000 description 4
- 206010053159 Organ failure Diseases 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 238000010988 intraclass correlation coefficient Methods 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 3
- 238000010989 Bland-Altman Methods 0.000 description 3
- 206010021137 Hypovolaemia Diseases 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 108010064719 Oxyhemoglobins Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 108010002255 deoxyhemoglobin Proteins 0.000 description 3
- 208000028659 discharge Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 239000010937 tungsten Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000009564 veno-arterial ECMO Methods 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 241000661823 Canopus Species 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010040893 Skin necrosis Diseases 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001142 back Anatomy 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000000701 chemical imaging Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000013156 embolectomy Methods 0.000 description 2
- 230000008508 epithelial proliferation Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000001255 hallux Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 210000001037 metacarpus Anatomy 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000001320 near-infrared absorption spectroscopy Methods 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002106 pulse oximetry Methods 0.000 description 2
- 238000013102 re-test Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000037152 sensory function Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 210000003270 subclavian artery Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000013334 tissue model Methods 0.000 description 2
- 230000000287 tissue oxygenation Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000009565 veno-venous ECMO Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 208000005417 Fleck corneal dystrophy Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020919 Hypervolaemia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027724 Mitral valve disease mixed Diseases 0.000 description 1
- 238000004497 NIR spectroscopy Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 241001074085 Scophthalmus aquosus Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000000142 acromioclavicular joint Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008822 capillary blood flow Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000009111 destination therapy Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005057 finger movement Effects 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940124975 inotropic drug Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001617 median nerve Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 210000003789 metatarsus Anatomy 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000000985 reflectance spectrum Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000008343 sublingual microcirculation Effects 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 210000000658 ulnar nerve Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/026—Measuring blood flow
- A61B5/0261—Measuring blood flow using optical means, e.g. infrared light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/13—Ophthalmic microscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0077—Devices for viewing the surface of the body, e.g. camera, magnifying lens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14552—Details of sensors specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14558—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters by polarisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/445—Evaluating skin irritation or skin trauma, e.g. rash, eczema, wound, bed sore
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4887—Locating particular structures in or on the body
- A61B5/489—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2503/00—Evaluating a particular growth phase or type of persons or animals
- A61B2503/04—Babies, e.g. for SIDS detection
- A61B2503/045—Newborns, e.g. premature baby monitoring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2505/00—Evaluating, monitoring or diagnosing in the context of a particular type of medical care
- A61B2505/03—Intensive care
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2576/00—Medical imaging apparatus involving image processing or analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/1464—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters specially adapted for foetal tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Optics & Photonics (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Liquid Crystal Substances (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1301490.7A GB2510176A (en) | 2013-01-28 | 2013-01-28 | Determining patient prognosis by microcirculation analysis |
| GB201312796A GB201312796D0 (en) | 2013-07-17 | 2013-07-17 | Neonatal microcirculation analysis |
| PCT/EP2014/051661 WO2014114814A1 (en) | 2013-01-28 | 2014-01-28 | Assessing circulatory failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2949276T3 true ES2949276T3 (es) | 2023-09-27 |
Family
ID=50029038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14701757T Active ES2949276T3 (es) | 2013-01-28 | 2014-01-28 | Evaluación de la insuficiencia circulatoria |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10987011B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2948042B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6542130B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2949276T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014114814A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210350927A1 (en) * | 2013-01-28 | 2021-11-11 | Oslo Universitetssykehus Hf | Assessing circulatory failure |
| JP6336949B2 (ja) * | 2015-01-29 | 2018-06-06 | 富士フイルム株式会社 | 画像処理装置及び画像処理方法、並びに内視鏡システム |
| JP6688164B2 (ja) * | 2016-06-09 | 2020-04-28 | 花王株式会社 | 皮膚毛細血管の観察方法 |
| CN111491555B (zh) | 2017-10-16 | 2024-06-21 | 麻省理工学院 | 用于非侵入性血液测量的系统、装置和方法 |
| JP7167132B2 (ja) * | 2018-03-26 | 2022-11-08 | テルモ株式会社 | 支援システム、支援方法、支援プログラム、および支援プログラムを記録した記録媒体 |
| US10485552B1 (en) * | 2018-12-28 | 2019-11-26 | Imad R. Makhoul | Apparatus and method for controlling systemic blood pressure in patients |
| EP3716207B1 (en) * | 2019-03-26 | 2023-11-29 | Active Medical B.V. | Method and apparatus for diagnostic analysis of the function and morphology of microcirculation alterations |
| US20220296108A1 (en) * | 2019-05-24 | 2022-09-22 | Seoul National University Hospital | Method and apparatus for quantitation of microcirculation |
| WO2021015843A1 (en) | 2019-07-24 | 2021-01-28 | Massachusetts Institute Of Technology | Finger inserts for a nailfold imaging device |
| US12203924B2 (en) | 2019-10-23 | 2025-01-21 | The Johns Hopkins University | Offset illumination capillaroscope |
| GB2589068A (en) | 2019-10-31 | 2021-05-26 | Odi Medical As | Probe |
| JPWO2021095472A1 (cg-RX-API-DMAC7.html) * | 2019-11-12 | 2021-05-20 | ||
| CN111657861B (zh) * | 2020-06-04 | 2022-02-25 | 浙江大学 | 基于双光子显微镜技术的溶栓药效评价方法 |
| CN112587105B (zh) * | 2020-12-11 | 2023-10-27 | 复旦大学附属中山医院 | 一种人体循环灌注状态评估系统 |
| WO2023011743A1 (en) | 2021-08-05 | 2023-02-09 | Odi Medical As | Assessing microcirculation |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2042075C (en) * | 1991-05-08 | 2001-01-23 | Branko Palcic | Endoscopic imaging system |
| US5769792A (en) * | 1991-07-03 | 1998-06-23 | Xillix Technologies Corp. | Endoscopic imaging system for diseased tissue |
| US6420709B1 (en) * | 1992-07-15 | 2002-07-16 | Optix Lp | Methods of minimizing scattering and improving tissue sampling in non-invasive testing and imaging |
| US5699797A (en) * | 1992-10-05 | 1997-12-23 | Dynamics Imaging, Inc. | Method of investigation of microcirculation functional dynamics of physiological liquids in skin and apparatus for its realization |
| US5553613A (en) * | 1994-08-17 | 1996-09-10 | Pfizer Inc. | Non invasive blood analyte sensor |
| US6104945A (en) * | 1995-08-01 | 2000-08-15 | Medispectra, Inc. | Spectral volume microprobe arrays |
| US20010041843A1 (en) * | 1999-02-02 | 2001-11-15 | Mark Modell | Spectral volume microprobe arrays |
| US5713364A (en) * | 1995-08-01 | 1998-02-03 | Medispectra, Inc. | Spectral volume microprobe analysis of materials |
| WO2000042910A1 (en) * | 1999-01-26 | 2000-07-27 | Newton Laboratories, Inc. | Autofluorescence imaging system for endoscopy |
| CA2385849A1 (en) * | 1999-09-23 | 2001-03-29 | Richard G. Nadeau | Medical applications of orthogonal polarization spectral imaging |
| US20020007122A1 (en) * | 1999-12-15 | 2002-01-17 | Howard Kaufman | Methods of diagnosing disease |
| US6377841B1 (en) * | 2000-03-31 | 2002-04-23 | Vanderbilt University | Tumor demarcation using optical spectroscopy |
| US20020165456A1 (en) * | 2001-03-26 | 2002-11-07 | Murat Canpolat | Estimation of the average size of white light scatterers in normal and cancerous tissue using light scattering spectrum |
| US6899675B2 (en) * | 2002-01-15 | 2005-05-31 | Xillix Technologies Corp. | Fluorescence endoscopy video systems with no moving parts in the camera |
| US20050154319A1 (en) * | 2002-01-15 | 2005-07-14 | Xillix Technologies Corporation | Fluorescence endoscopy video systems with no moving parts in the camera |
| US7706862B2 (en) * | 2003-04-17 | 2010-04-27 | Research Foundation Of The City University Of New York | Detecting human cancer through spectral optical imaging using key water absorption wavelengths |
| US8064976B2 (en) * | 2003-10-03 | 2011-11-22 | Can Ince | Systems and methods for sidesstream dark field imaging |
| US20060241364A1 (en) * | 2004-10-01 | 2006-10-26 | Academisch Medisch Centrum Of The University Van Amsterdam | System and method for imaging the reflectance of a substrate |
| US9131861B2 (en) | 2004-11-30 | 2015-09-15 | Academisch Medisch Centrum | Pulsed lighting imaging systems and methods |
| JP4743486B2 (ja) | 2005-05-24 | 2011-08-10 | 微小循環研究所 有限会社 | 指先の毛細血管血流による医療診断支援システム。 |
| US8214023B2 (en) * | 2006-09-21 | 2012-07-03 | Institute Of Critical Care Medicine | Microcirculation imaging |
| US20100185064A1 (en) * | 2007-01-05 | 2010-07-22 | Jadran Bandic | Skin analysis methods |
| US8903247B2 (en) | 2009-10-30 | 2014-12-02 | Cisco Technology, Inc. | Bidirectional multi-mode fiber interface |
| WO2011072401A1 (en) * | 2009-12-18 | 2011-06-23 | University Health Network | System and method for sub-surface fluorescence imaging |
| JP5797921B2 (ja) | 2011-03-30 | 2015-10-21 | 花王株式会社 | 体表評価方法および体表評価装置 |
| GB2510176A (en) * | 2013-01-28 | 2014-07-30 | Univ Oslo Hf | Determining patient prognosis by microcirculation analysis |
-
2014
- 2014-01-28 JP JP2015554205A patent/JP6542130B2/ja active Active
- 2014-01-28 EP EP14701757.8A patent/EP2948042B1/en active Active
- 2014-01-28 EP EP23177112.2A patent/EP4235152B1/en active Active
- 2014-01-28 ES ES14701757T patent/ES2949276T3/es active Active
- 2014-01-28 US US14/763,872 patent/US10987011B2/en active Active
- 2014-01-28 WO PCT/EP2014/051661 patent/WO2014114814A1/en not_active Ceased
-
2019
- 2019-06-12 JP JP2019109448A patent/JP6785339B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150359440A1 (en) | 2015-12-17 |
| EP4235152B1 (en) | 2025-04-02 |
| WO2014114814A1 (en) | 2014-07-31 |
| EP2948042B1 (en) | 2023-06-07 |
| EP4235152A2 (en) | 2023-08-30 |
| JP2016509505A (ja) | 2016-03-31 |
| US10987011B2 (en) | 2021-04-27 |
| JP6785339B2 (ja) | 2020-11-18 |
| JP2019188172A (ja) | 2019-10-31 |
| EP2948042A1 (en) | 2015-12-02 |
| EP4235152A3 (en) | 2023-09-27 |
| JP6542130B2 (ja) | 2019-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2949276T3 (es) | Evaluación de la insuficiencia circulatoria | |
| Cohn | Near-infrared spectroscopy: potential clinical benefits in surgery | |
| US20210350927A1 (en) | Assessing circulatory failure | |
| DePalma et al. | Bloodletting: past and present | |
| Wester et al. | Skin microvascular morphology and hemodynamics during treatment with veno-arterial extra-corporeal membrane oxygenation | |
| Lovětínská et al. | Free-flap monitoring: review and clinical approach | |
| Bruns et al. | How to administer near-infrared spectroscopy in critically ill neonates, infants, and children | |
| Garcia-Alix et al. | Hypoxic-ischaemic encephalopathy code: a systematic review for resource-limited settings | |
| Zaman et al. | Free flap pulse oximetry utilizing reflectance photoplethysmography | |
| Tschumi et al. | Post‐operative monitoring of free muscle transfers by Laser Doppler Imaging: A prospective study | |
| Marcinkevics et al. | Hyperspectral evaluation of skin blood oxygen saturation at baseline and during arterial occlusion | |
| Yao et al. | Hemorrhagic shock assessed by tissue microcirculatory monitoring: a narrative review | |
| Hove et al. | A prototype photoplethysmography-based cuffless device shows promising results in tracking changes in blood pressure | |
| Fraser Jr et al. | Neurologic monitoring for special cardiopulmonary bypass techniques | |
| Myatt | Pulse oximetry: what the nurse needs to know | |
| Kvernebo | Microcirculation and Tissue Perfusion Assessments for Complex Cardiovascular Disease Care | |
| JP2024530526A (ja) | 微小循環の評価 | |
| RU2161799C2 (ru) | Способ доклинической диагностики нарушений состояния здоровья детей и подростков | |
| Mattioli | Vital Signs: Parameters, Frequency, and Pediatric and Cardiac Early Warning Scores | |
| Abbas | Influences of Nursing Procedures and Factors Associated on the Vital Signs of Neonate | |
| Weaver | Electrical Cardiometry During Mechanical Ventilation: An Exploratory Study | |
| Wüstenberg et al. | Different swelling mechanisms in nasal septum (Kiesselbach area) and inferior turbinate responses to histamine: an optical rhinometric study | |
| Cordero et al. | Manual of Anaesthetic Monitoring in Small Animals | |
| LINDSAY et al. | Safe, time-saving, cost-effective ABPI measurement with automated machines. | |
| Ingram et al. | Clinical skills for healthcare assistants |